Fig. 5
circIGF1R mimics mitigate enhanced proliferation of HF-derived cardiac fibroblasts. (A) qRT-PCR of circIGF1R and IGF1R in non-HF and HF HCFs treated with mock or circIGF1R mimics (n = 4). RNA levels of circIGF1R and IGF1R were normalized to HPRT1. Data are depicted as fold change and normalized to mock group. Analyzed via unpaired t-test. (B) WST-1 assay in non-HF and HF HCFs treated with mock or circIGF1R mimics (n = 3). Data are depicted as fold change and normalized to non-HF mock group. Analyzed via 2-way ANOVA with Sidak’s post-hoc correction. (C) CFSE flow cytometry in non-HF and HF HCFs treated with mock or circIGF1R mimics (n = 3). Analyzed via 2-way ANOVA with Sidak’s post-hoc correction. (D) Representative histogram of CFSE flow cytometry in non-HF and HF HCFs treated with mock or circIGF1R mimics. (E) BrdU-ELISA in non-HF and HF HCFs treated with mock or circIGF1R mimics (n = 3). Data are depicted as fold change and normalized to non-HF mock group. Analyzed via 2-way ANOVA with Sidak’s post-hoc correction. (F) Ki67 immunofluorescence staining in non-HF and HF HCFs treated with mock or circIGF1R mimics (n = 3). Analyzed via 2-way ANOVA with Sidak’s post-hoc correction. (G) Representative images of Ki67 immunofluorescence staining in non-HF and HF HCFs treated with mock or circIGF1R mimics. White arrows indicate Ki67+ nuclei. Scale bar = 100 μm.
